Dosing intervals in intralymphatic immunotherapy

Clinical and Experimental Allergy

Volumn 46, Issue 3, 2016, Pages 504-507

  Hjálmsdóttir, Á ^a   Wackerle Men Y ^a   Duda, A ^a   Kundig T M ^a   Johansen, P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G4; OVALBUMIN; PLACEBO;

ALLERGEN IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL MATURATION; CLINICAL PROTOCOL; CLINICAL STUDY; CONTACT SENSITIZATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ANAPHYLAXIS; FOOD AND DRUG ADMINISTRATION; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INGUINAL LYMPH NODE; INTRACUTANEOUS TEST; INTRALYMPHATIC IMMUNOTHERAPY; MEMORY CELL; NONHUMAN; OUTCOME ASSESSMENT; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TIME TO TREATMENT; TREATMENT DURATION; VACCINATION; ANIMAL; DESENSITIZATION; DISEASE MODEL; HYPERSENSITIVITY; IMMUNOLOGY; INTRALYMPHATIC DRUG ADMINISTRATION; MOUSE; PROCEDURES; TREATMENT OUTCOME;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY; INJECTIONS, INTRALYMPHATIC; MICE; TREATMENT OUTCOME;

EID: 84959057953     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12657     Document Type: Article

References (10)

1. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008; 105:17908-12.
2. Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129:1290-6.
3. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013; 131:412-20.
4. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013; 132:1248-52. e5.
5. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003; 15:120-7.
6. Johansen P, Haffner AC, Koch F et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005; 35:568-74.
7. Johansen P, Senti G, Martinez Gomez JM, Wuthrich B, Bot A, Kundig TM. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol 2005; 35:3591-8.
8. Martineau P. Affinity measurements by competition ELISA. In: Kontermann R, Dübel S, eds. Antibody Engineering. Berlin Heidelberg: Springer-Verlag, 2010:657-65.
9. Goidl EA, Paul WE, Siskind GW, Benacerraf B. The effect of antigen dose and time after immunization on the amount and affinity of anti-hapten antibody. J Immunol 1968; 100:371-5.
10. Burks AW, Calderon MA, Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131:1288-96.